Eisai Licenses Nuvation Bio’s Taletrectinib for ROS1+ Lung Cancer in Europe and Asia
Eisai Co., Ltd. and Nuvation Bio Inc. announced an exclusive licensing agreement granting Eisai rights to develop and commercialize taletrectinib for ROS1-positive non-small cell lung cancer in Europe, Middle East, Canada, and parts of Asia.12
Nuvation Bio receives €50 million ($60 million) upfront payment and up to €145 million ($170 million) in milestone payments, plus double-digit tiered royalties up to high-teens on sales.12
Taletrectinib (IBTROZI in U.S./Japan) is approved in U.S., China, and Japan; Marketing Authorization Application planned for Europe in H1 2026.12
Nuvation Bio retains U.S. commercial rights and leads global development.12
No recent news found in search results on Alnylam's stock dip after sales data report.
Sources:
1. https://ng.investing.com/news/company-news/eisai-to-license-taletrectinib-for-ros1-lung-cancer-across-europe-asia-93CH-2284529